Metrics to compare | 1672 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1672PeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.3x | −8.1x | −0.4x | |
PEG Ratio | 0.98 | 0.09 | 0.00 | |
Price/Book | 4.0x | 3.4x | 2.6x | |
Price / LTM Sales | 3,786.0x | 10.3x | 3.0x | |
Upside (Analyst Target) | 170.5% | 39.9% | 53.2% | |
Fair Value Upside | Unlock | −3.3% | 9.0% | Unlock |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.